Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy

Stephen G. Schwartz, Harry W. Flynn, Wen Hsiang Lee, Elizabeth Ssemanda, Ann Margret Ervin

Research output: Contribution to journalArticle

Abstract

Background: Retinal detachment (RD) with proliferative vitreoretinopathy (PVR) often requires surgery. During surgery, a tamponade agent is needed to reduce the rate of recurrent retinal detachment. Objectives: The objective of this review was to evaluate the benefits and adverse outcomes of surgery with various tamponade agents. Search strategy: We searched the Cochrane Controlled Register (CENTRAL), MEDLINE, EMBASE, Latin America and Carribbean Health Sciences (LILACS) and the UK Clinical Trials Gateway (UKCTG). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 9 July 2009. Selection criteria: We included randomized clinical trials comparing patients treated with various tamponade agents. Data collection and analysis: Two individuals screened the search results independently. One study with two trials was eligible for inclusion in the review. Main results: One study with two trials was included in the review. The first trial randomized 151 eyes to receive either silicone oil or sulfur hexafluoride (SF6) gas tamponades; the second trial randomized 271 eyes to receive either silicone oil or perfluropropane (C3F8) gas tamponades. In patients with RD associated with PVR, pars plana vitrectomy and infusion of either silicone oil or perfluropropane gas appear comparable for a broad variety of cases. Sulfur hexafluoride gas was associated with worse anatomic and visual outcomes than either silicone oil or perfluropropane gas. Authors' conclusions: The use of either C3F8 or silicone oil appears reasonable for most patients with RD associated with PVR. Because there do not appear to be any major differences in outcomes between the two agents, the choice of a tamponade agent should be individualized for each patient.

Original languageEnglish (US)
Article numberCD006126
JournalThe Cochrane database of systematic reviews
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Proliferative Vitreoretinopathy
Silicone Oils
Retinal Detachment
Gases
Sulfur Hexafluoride
perflutren
Temazepam
Latin America
Vitrectomy
MEDLINE
Patient Selection
Language
Randomized Controlled Trials
Clinical Trials
Databases
Health

Keywords

  • Fluorocarbons [*administration & dosage]
  • Humans
  • Randomized controlled trials as topic
  • Recurrence [prevention & control]
  • Retinal detachment [etiology; prevention & control; *therapy]
  • Silicone oils [*administration & dosage]
  • Sulfur hexafluoride [* administration & dosage]
  • Vitreoretinopathy, proliferative [*complications]

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. / Schwartz, Stephen G.; Flynn, Harry W.; Lee, Wen Hsiang; Ssemanda, Elizabeth; Ervin, Ann Margret.

In: The Cochrane database of systematic reviews, No. 4, CD006126, 2009.

Research output: Contribution to journalArticle

@article{f97108f7cc904d30a02a4ae178e89755,
title = "Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy",
abstract = "Background: Retinal detachment (RD) with proliferative vitreoretinopathy (PVR) often requires surgery. During surgery, a tamponade agent is needed to reduce the rate of recurrent retinal detachment. Objectives: The objective of this review was to evaluate the benefits and adverse outcomes of surgery with various tamponade agents. Search strategy: We searched the Cochrane Controlled Register (CENTRAL), MEDLINE, EMBASE, Latin America and Carribbean Health Sciences (LILACS) and the UK Clinical Trials Gateway (UKCTG). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 9 July 2009. Selection criteria: We included randomized clinical trials comparing patients treated with various tamponade agents. Data collection and analysis: Two individuals screened the search results independently. One study with two trials was eligible for inclusion in the review. Main results: One study with two trials was included in the review. The first trial randomized 151 eyes to receive either silicone oil or sulfur hexafluoride (SF6) gas tamponades; the second trial randomized 271 eyes to receive either silicone oil or perfluropropane (C3F8) gas tamponades. In patients with RD associated with PVR, pars plana vitrectomy and infusion of either silicone oil or perfluropropane gas appear comparable for a broad variety of cases. Sulfur hexafluoride gas was associated with worse anatomic and visual outcomes than either silicone oil or perfluropropane gas. Authors' conclusions: The use of either C3F8 or silicone oil appears reasonable for most patients with RD associated with PVR. Because there do not appear to be any major differences in outcomes between the two agents, the choice of a tamponade agent should be individualized for each patient.",
keywords = "Fluorocarbons [*administration & dosage], Humans, Randomized controlled trials as topic, Recurrence [prevention & control], Retinal detachment [etiology; prevention & control; *therapy], Silicone oils [*administration & dosage], Sulfur hexafluoride [* administration & dosage], Vitreoretinopathy, proliferative [*complications]",
author = "Schwartz, {Stephen G.} and Flynn, {Harry W.} and Lee, {Wen Hsiang} and Elizabeth Ssemanda and Ervin, {Ann Margret}",
year = "2009",
doi = "10.1002/14651858.CD006126.pub2",
language = "English (US)",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy

AU - Schwartz, Stephen G.

AU - Flynn, Harry W.

AU - Lee, Wen Hsiang

AU - Ssemanda, Elizabeth

AU - Ervin, Ann Margret

PY - 2009

Y1 - 2009

N2 - Background: Retinal detachment (RD) with proliferative vitreoretinopathy (PVR) often requires surgery. During surgery, a tamponade agent is needed to reduce the rate of recurrent retinal detachment. Objectives: The objective of this review was to evaluate the benefits and adverse outcomes of surgery with various tamponade agents. Search strategy: We searched the Cochrane Controlled Register (CENTRAL), MEDLINE, EMBASE, Latin America and Carribbean Health Sciences (LILACS) and the UK Clinical Trials Gateway (UKCTG). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 9 July 2009. Selection criteria: We included randomized clinical trials comparing patients treated with various tamponade agents. Data collection and analysis: Two individuals screened the search results independently. One study with two trials was eligible for inclusion in the review. Main results: One study with two trials was included in the review. The first trial randomized 151 eyes to receive either silicone oil or sulfur hexafluoride (SF6) gas tamponades; the second trial randomized 271 eyes to receive either silicone oil or perfluropropane (C3F8) gas tamponades. In patients with RD associated with PVR, pars plana vitrectomy and infusion of either silicone oil or perfluropropane gas appear comparable for a broad variety of cases. Sulfur hexafluoride gas was associated with worse anatomic and visual outcomes than either silicone oil or perfluropropane gas. Authors' conclusions: The use of either C3F8 or silicone oil appears reasonable for most patients with RD associated with PVR. Because there do not appear to be any major differences in outcomes between the two agents, the choice of a tamponade agent should be individualized for each patient.

AB - Background: Retinal detachment (RD) with proliferative vitreoretinopathy (PVR) often requires surgery. During surgery, a tamponade agent is needed to reduce the rate of recurrent retinal detachment. Objectives: The objective of this review was to evaluate the benefits and adverse outcomes of surgery with various tamponade agents. Search strategy: We searched the Cochrane Controlled Register (CENTRAL), MEDLINE, EMBASE, Latin America and Carribbean Health Sciences (LILACS) and the UK Clinical Trials Gateway (UKCTG). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 9 July 2009. Selection criteria: We included randomized clinical trials comparing patients treated with various tamponade agents. Data collection and analysis: Two individuals screened the search results independently. One study with two trials was eligible for inclusion in the review. Main results: One study with two trials was included in the review. The first trial randomized 151 eyes to receive either silicone oil or sulfur hexafluoride (SF6) gas tamponades; the second trial randomized 271 eyes to receive either silicone oil or perfluropropane (C3F8) gas tamponades. In patients with RD associated with PVR, pars plana vitrectomy and infusion of either silicone oil or perfluropropane gas appear comparable for a broad variety of cases. Sulfur hexafluoride gas was associated with worse anatomic and visual outcomes than either silicone oil or perfluropropane gas. Authors' conclusions: The use of either C3F8 or silicone oil appears reasonable for most patients with RD associated with PVR. Because there do not appear to be any major differences in outcomes between the two agents, the choice of a tamponade agent should be individualized for each patient.

KW - Fluorocarbons [administration & dosage]

KW - Humans

KW - Randomized controlled trials as topic

KW - Recurrence [prevention & control]

KW - Retinal detachment [etiology; prevention & control; therapy]

KW - Silicone oils [administration & dosage]

KW - Sulfur hexafluoride [ administration & dosage]

KW - Vitreoretinopathy, proliferative [complications]

UR - http://www.scopus.com/inward/record.url?scp=77950136382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950136382&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD006126.pub2

DO - 10.1002/14651858.CD006126.pub2

M3 - Article

C2 - 19821354

AN - SCOPUS:77950136382

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 4

M1 - CD006126

ER -